Siemens Healthineers misses Q3 forecasts due to slow China
Adds Q2 EBIT and outlook from paragraph 2
July 31 (Reuters) -German medical technology company Siemens Healthineers SHLG.DE reported third-quarter sales and earnings below expectations on Wednesday, hit by continued order delays in China.
It reported a quarterly revenue of 5.42 billion euros ($5.87 billion) and adjusted earnings before interest and tax (EBIT) of 825 million euros, while analysts were expecting a revenue of 5.54 billion and an EBIT of 856 million in a poll compiled by Vara Research.
The company confirmed its full-year outlook for comparable revenue growth of between 4.5% and 6.5%, and adjusted basic earnings per share of 2.10 euros to 2.30 euros.
However, it lowered the full-year guidance for the Imaging business, its biggest by sales, and now expects a comparable revenue growth of between 4.5% and 5.5%, compared with the 6% to 8% it had forecast in the 2023 annual report.
($1 = 0.9239 euros)
Reporting by Marleen Kaesebier and Louis van Boxel-Woolf in Gdansk; Editing by Milla Nissi
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
